FDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk
The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat Type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events.
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound.
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
Novo Nordisk (NVO) concluded the recent trading session at $56.09, signifying a -1.11% move from its prior day's close.
Novo Nordisk's Akero Therapeutics Buy Targets Eli Lilly's Lead
Novo Nordisk A/S NYSE: NVO recently announced plans to acquire Akero Therapeutics. The deal, which is valued at around $4.7 billion, is scheduled to close early in 2026.
Focus: Inside Novo Nordisk's 'Club 5,000' as Danish staff cuts gain pace
Romel Amineh is one of a fast-growing group of Novo Nordisk workers in Denmark laid off as the drugmaker battles to cut costs and revive its fortunes in a fiercely competitive global obesity drug market. They call themselves the "Club 5,000".
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
Novo Nordisk A/S (NVO) M&A Call Transcript
Novo Nordisk A/S (NVO) M&A Call October 9, 2025 8:00 AM EDT Company Participants Jacob Martin Rode - Head of Investor Relations Maziar Doustdar - President, CEO & Member of the Management Board Ludovic Helfgott - Executive VP of Product & Portfolio Strategy and Member of Management Board Martin Lange - EVP of R&D, CSO and Member of the Management Board Conference Call Participants Harry Sephton - UBS Investment Bank, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Peter Verdult - BNP Paribas Exane, Research Division Conor MacKay - BMO Capital Markets Equity Research Michael Nedelcovych - TD Cowen, Research Division Michael Leuchten - Jefferies LLC, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Thibault Boutherin - Morgan Stanley, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
2 Beaten-Down Stocks Primed for a Comeback
Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present.
Novo Nordisk: The Bottom Is In
NVO trades at a rare dislocation with a forward P/E ~15% below sector and EPS growth ~66% above, primed for the 2026 healthcare re-rating. Its semaglutide engine (Wegovy growth, CagriSema pipeline, high-dose oral filing) anchors durable expansion despite Lilly's dominance. Pricing, supply, and concentration risks exist, but oversold RSI and macro tailwinds set up 20–30% upside with limited downside.
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
The Truth About Novo Nordisk: 4 Myths That Don't Hold Up
Novo Nordisk remains a strong buy despite recent market pessimism, with key growth catalysts on the horizon. NVO's Wegovy, especially at higher doses, rivals Eli Lilly's Zepbound in weight loss and offers superior cardiovascular benefits, maintaining competitive strength. Concerns over tariffs and compounded drugs are overblown; NVO's US manufacturing footprint and legal actions minimize these risks.
